Ó£ÌÒÊÓƵapp

[Skip to Navigation]
Sign In

Year

Day

September 4, 2024
Original Investigation

Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial

Abstract Full Text
open access
JAMA Cardiol. Published online September 4, 2024. doi:10.1001/jamacardio.2024.2781

This substudy of the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) randomized clinical trial investigates if treatment with aficamten improves exercise response beyond peak oxygen uptake measured by cardiopulmonary exercise testing in obstructive hypertrophic cardiomyopathy.

Brief Report

Genome-Wide Association Study of Accessory Atrioventricular Pathways

Abstract Full Text
JAMA Cardiol. Published online September 4, 2024. doi:10.1001/jamacardio.2024.2684

This genome-wide association study evaluates the genetics of atrioventricular pathways.

Cardiovascular Images

Sudden Hemodynamic Deterioration of a 75-Year-Old Woman With Progressive Jaw Pain

Abstract Full Text
has active quiz has multimedia
JAMA Cardiol. Published online September 4, 2024. doi:10.1001/jamacardio.2024.2695

This case report describes a diagnosis of left ventricular anterior free-wall rupture in a patient given anticoagulant treatment for subacute myocardial infarction.

Comment & Response

Addressing Evidence Gaps in Coronary Revascularization Trials

Abstract Full Text
JAMA Cardiol. Published online September 4, 2024. doi:10.1001/jamacardio.2024.2778
September 2, 2024
Original Investigation

Lesion-Level Effects of LDL-C–Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial

Abstract Full Text
free access
JAMA Cardiol. Published online September 2, 2024. doi:10.1001/jamacardio.2024.3200

This post hoc analysis of a randomized clinical trial analyzes imaging data for atheroma volume at the lesion level from patients who received intensive lipid-lowering therapy with alirocumab plus statin compared with a statin alone.

From the Heart

AI in Cardiology

Echoes of Concern—AI and Moral Agency in Medicine

Abstract Full Text
JAMA Cardiol. Published online September 2, 2024. doi:10.1001/jamacardio.2024.3512

This essay describes concerns that use of artificial intelligence (AI) as a replacement rather than a supplement in the provision of medical care may lead to loss of the art of medicine and the collaborative partnership between physician and patient.

Invited Commentary

What We Have Learned About Reducing Low-Density Lipoprotein Cholesterol and Coronary Plaques

Abstract Full Text
free access
JAMA Cardiol. Published online September 2, 2024. doi:10.1001/jamacardio.2024.3213
×